Browsing: drug

CHINA / SOCIETY China’s first AI-assisted innovative drug approved for marketing: media

Jim Cramer is flagging an Amgen drug that Wall Street has largely ignored, and he thinks the cardiovascular opportunity behind it could rival the most valuable pharmaceutical market ever created.

I knew I’d officially become a “longevity influencer” this month when a company called Generation Lab reached out to offer me the chance to write about—and even receive—their new rejuvenation treatment, an injectable combination of two existing drugs which they call 1 Generation.

ALTERITY THERAPEUTICS LIMITED (ATHE) filed an annual report describing its development-stage neurology business focused on ATH434 for multiple system atrophy (MSA) and other Parkinsonian disorders. ATH434 is the lead and highly concentrated asset; Alterity reported positive FDA feedback and End‑of‑Phase 2 alignment on key elements of a registrational Phase 3 program.

The deal is valued at over $1.5 billion and will grant Sentivera global rights to develop, manufacture, and commercialize a preclinical drug targeting type 2 inflammatory diseases, excluding Greater China.